Abstract
Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have